Semaglutide Delivers 13.6% Weight Loss in Real-World Use Despite High Dropout Rates
A Danish real-world study finds semaglutide drives substantial weight loss, but 53% of patients stop or pause treatment within 12 months.
Summary
A retrospective study from a Danish primary care practice tracked 206 adults prescribed semaglutide for weight management over 12 months. Despite widespread discontinuation — 38% permanently stopped and 15% temporarily paused — those who stayed on treatment lost an average of 13.6% of body weight. Notably, real-world patients were titrated more slowly and to lower doses than clinical trial protocols recommend. Only 30% reached the maximum approved dose of 2.4 mg/week. These findings confirm semaglutide's meaningful real-world effectiveness while highlighting that adherence and dose titration gaps remain major clinical challenges outside the controlled trial setting.
Detailed Summary
Semaglutide (Wegovy) has demonstrated remarkable efficacy in randomized controlled trials, but how it performs in everyday clinical practice is a critical question for clinicians and patients alike. This real-world study from a single Danish general practice offers a grounded look at how patients actually use the drug — and where gaps from trial conditions emerge.
Researchers conducted a retrospective observational study of 206 adults prescribed semaglutide for weight management between December 2022 and May 2024, shortly after its Danish market launch. The cohort was predominantly female (76%), with a mean age of 48 years and a mean baseline weight of 105 kg. The primary outcome was relative body weight change at 12 months among those who remained on treatment.
The most striking finding was the high discontinuation rate. Within 12 months, 38% had permanently stopped semaglutide and 15% had paused it, leaving only about 48% still on treatment. Among those continuing, dosing fell well below trial standards: 40% were on 1.0 mg/week or less, 30% on 1.7 mg/week, and only 30% had reached the target 2.4 mg/week dose. Despite this, patients who remained on treatment achieved a clinically meaningful mean weight loss of 13.6% — a result approaching trial-level outcomes.
For clinicians, this study underscores two pressing issues: discontinuation management and dose optimization. The majority of patients stopping or underdosing suggests real-world tolerability challenges, cost pressures, or inadequate titration support. Interventions to improve adherence could substantially amplify population-level outcomes.
Caveats are significant. The study involved only one practice with 206 participants, limiting generalizability. No data on reasons for discontinuation were reported. The summary is based on the abstract only, so granular data on side effects, demographics, and confounders is unavailable.
Key Findings
- Patients remaining on semaglutide for 12 months lost an average of 13.6% of body weight.
- 53% of patients permanently or temporarily discontinued semaglutide within 12 months.
- Only 30% of real-world patients reached the maximum approved dose of 2.4 mg/week.
- Real-world titration was slower and reached lower maintenance doses than clinical trial protocols.
- 76% of the treated cohort were women, reflecting the demographic skew in obesity treatment.
Methodology
Retrospective observational study of 206 adults from a single Danish general practice, prescribed semaglutide between December 2022 and May 2024. The primary outcome was relative mean body weight change at 12 months among non-discontinuers with available baseline and follow-up weights. No control group was used.
Study Limitations
Single-practice design with only 206 participants severely limits generalizability to broader populations or healthcare systems. Reasons for discontinuation and data on side effects or comorbidities are not reported in the abstract. The summary is based on the abstract only, as the full paper is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: